Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Padeliporfin - ImPact Biotech

Next Previous
Search
Drug Profile

Padeliporfin - ImPact Biotech

Alternative Names: Padeliporfin di-potassium - ImPact Biotech; Padeliporfin ImPACT; Padeliporfin VTP; Palladium bacteriopheophorbide monolysine taurine; Stakel; TOOKAD Soluble; WST-11

Latest Information Update: 06 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Steba Laboratories
  • Developer ImPact Biotech
  • Class Antineoplastics; Eye disorder therapies; Porphyrins; Small molecules
  • Mechanism of Action Photosensitisers; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Urogenital cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase III Urogenital cancer
  • Phase I/II Renal cancer
  • Phase I Adenocarcinoma; Lung cancer
  • Preclinical Degenerative myopia; Non-small cell lung cancer; Pancreatic cancer
  • Suspended Choroidal neovascularisation
  • No development reported Cholangiocarcinoma; Oesophageal cancer

Most Recent Events

  • 28 Apr 2025 Updated efficacy and adverse event data from a phase III ENLIGHTED trial in Urogenital cancer released by Impact Biotech
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Oesophageal-cancer(In the elderly, Metastatic disease, In adults) in Israel (IV, Infusion)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Oesophageal-cancer(In the elderly, Metastatic disease, In adults) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top